Cochlear (ASX: COH)‘s stock had its “underperform” rating reaffirmed by Credit Suisse in a research note issued on Wednesday. They currently have a $77.08 (74 AUD) price target on the stock.

Several other analysts have also recently commented on the stock. Analysts at Macquarie reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Friday, November 23rd. They now have a $71.35 price target on the stock. Separately, analysts at Goldman Sachs reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Monday, November 12th. They now have a $67.71 price target on the stock. Finally, analysts at Nomura reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Tuesday, October 30th. They now have a $70.31 price target on the stock.

Cochlear opened at 74.450 on Wednesday. Cochlear has a 1-year low of A$52.250 and a 1-year high of A$76.120. The company has a market cap of A$4.234 billion and a price-to-earnings ratio of 74.92.

Cochlear Limited (Cochlear) is an Australia-based company, which operates in the implantable hearing device industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.